ARACHIDONIC ACID IN PULMONARY LARGE CELL CARCINOMA

花生四烯酸在肺大细胞癌中的作用

基本信息

  • 批准号:
    4692203
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
  • 资助国家:
    美国
  • 起止时间:
  • 项目状态:
    未结题

项目摘要

Clinically, large cell carcinoma (LCC) is by far the least treatable lung cancer. Characterization of this subclass of carcinoma by an exclusive cell type is not possible even under electron microscopic examination. Thus, investigation of the biochemical and morphological features of human LCC is warranted. The pathobiology of human lung cancer is often associated with the biosynthesis and release of various biologically active substances by malignant cells. A number of studies have indicated that prostaglandins (PGs) and other eicosanoids may play a role in the pathobiology of malignant disease, i.e., tumor promotion, cellular proliferation and differentiation. One metabolite of arachidonic acid (AA), prostaglandin E2 (PGE2), has been implicated as a mediator of hypercalcemia associated with certain lung cancers. The leukotrienes participate in the initiation of immune and inflammatory responses and thus could play a role in host defense mechanisms in human lung cancer. Studies of the metabolism of AA were undertaken to determine the pathways of AA metabolism and the relevance of this metabolism in human LCC. Our preliminary studies demonstrated that a homogenous human LCC line, NCI-H460, unlike any other known human lung carcinoma cell line maintained in this laboratory possesses significantly higher PGE2 synthesis (6 fold) in the early passage (15) as compared to that in the late passage (93). Furthermore, the morphology of this cell line has changed. Originaly diagnosed as LCC (containing large amounts of endoplasmic reticulum), it was reclassified as a small cell carcinoma (exhibiting endocrine cell features) in passage 15 and it is now described as an oncocytoma (containing large numbers of mitochondria). The mechanism for such an alteration is unknown. To examine the role of AA metabolism in tumor development in vivo, cells from early and late passages of NCI-H460 will be injected into nude mice. The profile of AA metabolism in the primary tumor as well as in the metastases formation will be investigated.
在临床上,大细胞癌(LCC)是迄今为止最难治疗的肺

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

S S LAU其他文献

S S LAU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('S S LAU', 18)}}的其他基金

XENOBIOTIC METABOLISM BY PROSTAGLANDIN ENDOPEROXIDE SYNTHETASE
前列腺素内过氧化物合成酶的异生代谢
  • 批准号:
    4692193
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
ARACHIDONIC ACID METABOLISM IN HUMAN LUNG ADENOCARCINOMA
人肺腺癌中的花生四烯酸代谢
  • 批准号:
    4692202
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:
MOLECULAR TOXICOLOGY AND DRUG DEVELOPMENT
分子毒理学和药物开发
  • 批准号:
    3963318
  • 财政年份:
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Preoperative molecular diagnosis with novel follicular thyroid carcinoma-specific markers using cytology and blood samples
使用细胞学和血液样本进行新型滤泡性甲状腺癌特异性标记物的术前分子诊断
  • 批准号:
    23K08060
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Impact of sarcopenia and creation of novel therapeutic targets by immunotherapeutic resistance mechanisms in hepatocellular carcinoma
肌少症的影响以及通过免疫治疗耐药机制创建新的治疗靶点对肝细胞癌的影响
  • 批准号:
    23K08106
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Combination therapy for renal cell carcinoma using oncolytic virus G47d
使用溶瘤病毒 G47d 联合治疗肾细胞癌
  • 批准号:
    23K08752
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of transcatheter arterial embolization for controlling hypoxia in hepatocellular carcinoma
经导管动脉栓塞控制肝细胞癌缺氧的研究进展
  • 批准号:
    23K07075
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Dissecting the roles of iron and hemojuvelin in hepatocellular carcinoma
剖析铁和血幼素在肝细胞癌中的作用
  • 批准号:
    478251
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Operating Grants
Analysis of the antioxidant function of xCT in lymphatic endothelial cells and its significance in oral squamous cell carcinoma.
淋巴管内皮细胞xCT抗氧化功能分析及其在口腔鳞癌中的意义
  • 批准号:
    23K16139
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Search for therapeutic target molecules based on temporal hierarchical analysis of Oral squamous cell carcinoma and functional RNA molecules
基于口腔鳞状细胞癌和功能RNA分子的时间层次分析寻找治疗靶分子
  • 批准号:
    23K16142
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Investigating a new vulnerability in oral squamous cell carcinoma
研究口腔鳞状细胞癌的新脆弱性
  • 批准号:
    10714352
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
"Role of Amplified Protein Kinases in Head and Neck Squamous Cell Carcinoma Progression and Therapy Resistance."
“扩增的蛋白激酶在头颈鳞状细胞癌进展和治疗耐药中的作用。”
  • 批准号:
    10725901
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
NASH-肝细胞癌免疫治疗反应的决定因素
  • 批准号:
    10735947
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了